Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 2009 and is headquartered in Oslo, Norway.
Research context
Nordic Nanovector ASA appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
Nordic Nanovector ASA is currently in a long term uptrend where the price is trading 4.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Nordic Nanovector ASA's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 19.8% to $-111M since the same quarter in the previous year.
Finally, its free cash flow grew by 35.3% to $-65M since the same quarter in the previous year.
Based on the above factors, Nordic Nanovector ASA gets an overall score of 4/5.